Prepare for Upcoming Events With This Webinar
Research - Our March webinar focused primarily on recent events in the bio/pharma space; some actionable ideas for the next few weeks; and of course, politics (AHCA vote … Continue Reading
Read NowResearch
Profits From One, Adding To Another
Research - Note – Jake here. I’m just resurfacing after the birth of our second child early this week. Sorry for the delay in returning emails, and … Continue Reading
Premium: Read Now
February Webinar: Your Questions, Answered
Research - A recording of last night’s webinar is ready and available for on-demand viewing. This month focused almost exclusively on your requested topics/companies. Timestamps: 2:00 Macro … Continue Reading
Premium: Read Now
The Well-Worn Path of ERTs
Long Ideas - Last July, Ultragenyx Pharmaceutical (RARE) released positive results from a phase 3 study of its enzyme replacement therapy rhGUS (recombinant human beta-glucuronidase) in the lysosomal … Continue Reading
Read Now
See Inefficient Markets In Action
Research - Over last weekend, Pharmathene (PIP) affected a special one-time cash dividend of $2.91 per share of common stock. This is money received from its long-running … Continue Reading
Premium: Read Now
Can ArQule’s Tivantinib Cut It? Reasons To Be A Skeptic
Research - Despite continued claims to the contrary, ArQule is a fairly weak MET inhibitor, and some publications question this proposed mechanism entirely
Premium: Read NowStart Planning For Q1 With Our Latest Biotech Webinar
Research - Last night’s webcast is now available for replay. Topics of discussion included the Trump presidency, drug prices, and healthcare reform in 2017. We also introduced … Continue Reading
Premium: Read Now